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An individual’s disease risk is determined by the compounded action of both common variants, inherited from remote ancestors, that
segregated within the population and rare variants, inherited from recent ancestors, that segregated mainly within pedigrees. Next-
generation sequencing (NGS) technologies generate high-dimensional data that allow a nearly complete evaluation of genetic variation.
Despite their promise, NGS technologies also suffer from remarkable limitations: high error rates, enrichment of rare variants, and a large
proportion of missing values, as well as the fact that most current analytical methods are designed for population-based association
studies. To meet the analytical challenges raised by NGS, we propose a general framework for sequence-based association studies that
can use various types of family and unrelated-individual data sampled from any population structure and a universal procedure that
can transform any population-based association test statistic for use in family-based association tests. We develop family-based func-
tional principal-component analysis (FPCA) with or without smoothing, a generalized T2, combined multivariate and collapsing
(CMC) method, and single-marker association test statistics. Through intensive simulations, we demonstrate that the family-based
smoothed FPCA (SFPCA) has the correct type I error rates and much more power to detect association of (1) common variants, (2)
rare variants, (3) both common and rare variants, and (4) variants with opposite directions of effect from other population-based or
family-based association analysis methods. The proposed statistics are applied to two data sets with pedigree structures. The results
show that the smoothed FPCA has a much smaller p value than other statistics.Introduction
Resequencingof exomes—andultimately,whole genomes—
generate unprecedentedly massive, high-dimensional
genetic-variation data that allow a nearly complete
evaluation of genetic variation, including several million
common (>5% population frequency), low-frequency
(>1% and < 5% population frequency), and rare variants
(<1% population frequency) in typical human genomes,
and provides a powerful tool for the comprehensive cata-
loging of human genetic variation and the identification
of the association of the entire allele-frequency spectrum
of genetic variation.1,2 Limitations of next-generation
sequencing (NGS) technologies include high error rates,
enrichment of rare variants, and a large proportion of
missing values.3–7
It is hypothesized that common variants are derived
from distant ancestors and rare variants are of recent
origin.8 An individual’s disease risk is likely to arise from
the compounded action of common variants that segre-
gated in the population and rare variants that arose
recently in extended pedigrees. There has been a gradual
realization that common variants play a less-significant
role in causing disease than that played by rare variants
that are of recent origin; accordingly, during the past
several years, genetic studies of complex diseases have
undergone a paradigm shift from identifying common
risk variants to identifying either rare risk variants or
both common and rare risk variants.9 The current popular
statistical method for testing the association of rare vari-
ants is the population-based association test. However,1Human Genetics Center and Division of Biostatistics, The University of Texa
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grees.8,10,11 Given that an individual rare variant would
have a relatively small impact on the common disease
and that rare variants have very low population frequen-
cies, the power the current analytical platforms have in
testing the association of rare variants is limited, regardless
of whether they are traditional variant-by-variant analysis
methods or the recently developed group tests. An
outstanding question is how to meet the analytical
challenges raised by NGS through integration of all risk-
associated common and rare variants that segregate in
populations or pedigrees over several generations, and, in
so doing, efficiently use NGS for the identification of the
association of rare variants with disease.
To achieve this goal, we propose a general framework for
association studies that uses data sampled from pedigrees
with a complex structure and unrelated individuals from
structured populations as well as an entire allelic spectrum
of genetic variants.12 Typical pedigrees include: parent-
offspring trios, sibling pairs, extended pedigrees with
multiple affected and unaffected individuals, multigenera-
tional families, and families and related individuals from
structured populations.
The proposed approach has several remarkable features.
First, it can be applied to various types of genetic data.
Specifically, it does not require assumptions as to how
the individuals might be related and allows for unknown
or partially known pedigree structures. The individuals
can come from structured populations, such as consan-
guineous populations and admixed populations. The
genetic variants can be common, rare, or both commons School of Public Health, Houston, TX 77030, USA
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and rare. Second, the mathematical disadvantage of tradi-
tional linkage analysis is its use of the likelihood approach.
Specification of likelihood functions for complex genetic
data with multiple pedigrees, large numbers of unrelated
individuals, and multiple rare and common variants in
a genomic region is difficult, as is the development of algo-
rithms for estimation of the parameters from such
complex likelihood functions. We present a statistical
method that is simple, easy to implement, and therefore
computationally feasible for NGS data. Third, the inclu-
sion of families in association studies has the potential
to enhance our ability to enrich for rare risk or for
protective variants that occur in the pedigrees over several
generations, and hence substantially increase their
power. Fourth, joint analysis of linkage and association
can effectively use the observed transmission (linkage)
information in the pedigrees, the linkage disequilibrium
(LD) information hidden in the history of populations,
rare variants segregating in the pedigrees, and common
variants segregating in the population. Fifth, the transmis-
sion pattern in the pedigrees allows for easy correction
of sequencing errors. Sixth, the genotype data of other
members of the pedigrees provide useful information for
inferring the missing genotypes of the individuals in the
pedigrees. Seventh, family data allow for control of hetero-
geneity and population substructures. Eighth, this
approach can use both pedigree and unrelated individual
data; hence, it provides a highly flexible general framework
for association studies of complex disease.
Extension of the population-basedassociation-analysis
methods designed for NGS to the family-based or mixed
family-based and population-based association studies
for NGS is a core of the proposed general framework
for association studies. The key to such extensions is
calculation of the covariance matrix of multiple genetic
variants in the genome region or the functional principal
scores between related individuals. Therefore, motivated
by case-control association testing for related individuals
who have population substructure,13–16 we first derive
the formulas for calculation of the covariance matrices
of genetic variance and the functional principal-compo-
nent scores. Then, with the aid of these formulas, we
extend the combined multivariate and collapsing (CMC)
method,9 generalized T2,17 and functional principal-
component analysis (FPCA)18 statistics for population-
based association studies to family-based or mixed
family-based and population-based association studies.
To evaluate the statistics’ performance, we use large-scale
simulations to calculate the type I error rates and compare
the power of several statistics with simulated data
containing both pedigrees and unrelated individuals. For
further evaluation of their performance, statistics devel-
oped in this report are applied to the Framingham Heart
Study (FHS) data set and childhood-onset asthma studies.
A program for implementing the developed statistical
methods can be downloaded from our website (see Web
Resources).The AmericMaterial and Methods
We extend four population-based association tests for NGS to
a general case that has multiple families and unrelated individuals
present in the samples.
The Generalized T2 Test for Families and Unrelated
Individuals
Consider n sampled individuals from multiple families or unre-
lated individuals. Assume that each individual has T genetic vari-
ants. Suppose that the genotypes of the ith individual at the tth
genetic variant site are denoted by atat ; atAt, and AtAt , respec-
tively. Assume that At is a risk allele. Define an indicator variable
for the genotype as
Zti ¼
8<
:
2 AtAt
1 Atat
0 atat
; i ¼ 1;2;.;n; t ¼ 1;2;.;T:
Let
Zt ¼ Zt1;.;ZtnT and Z ¼ hZ1T ;.; ZTTiT :
Define Dr ¼ ½u1;.;unT and Dp ¼ ½1;1;.;1T , a column vector
of 1 of length n, where
ui ¼

1 if i is a case
0 if i is a control:
Define
H ¼
2
6666666664

Dr  nc
n
Dp
T
0 / 0
0

Dr  nc
n
Dp
T
/ 0
/ / / /
0 0 /

Dr  nc
n
Dp
T
3
7777777775
¼ IðTÞ5

Dr  nc
n
Dp
T
(Equation 1)
where nc is the number of affected individuals, IðTÞ is a T dimen-
sional identity matrix, and 5 denotes the Kronecker product of
two matrices.
The generalized T2 statistic with pedigree structures is defined as
T2F ¼ ðHZÞTG1HZ; (Equation 2)
where G ¼ covðHZ;HZÞ.
Let
X
z
¼
2
664
s11 s12 / s1T
s21 s22 / s2T
/ / / /
sT1 sT2 / sTT
3
775; (Equation 3)
where sij ¼ covðZi1;Zj1Þ.
It can be shown that (Appendix A)
Lz ¼ covðZ;ZÞ ¼ Sz5F; (Equation 4)
where F is the kinship matrix and defined as
F ¼
2
664
1þ h1 2f12 / 2f1n
2f21 1þ h2 / 2f2n
/ / / /
2fn1 2fn2 . 1þ hn
3
775; (Equation 5)an Journal of Human Genetics 90, 1028–1045, June 8, 2012 1029
hi is the inbreeding coefficient of individual i, and fij is the kinship
coefficient between individuals i and j.
The matrix Sz can be estimated by
S^z ¼ 1
n T
Xn
i¼1
ðZi  ZÞðZi  ZÞT ; (Equation 6)
where
Zi ¼

Z1i ;Z
2
i ;.;Z
T
i
T
;Z ¼ 1
n
Xn
i¼1
Zi:
The covariance matrix G is calculated as follows:
G ¼ covðHZ;HZÞ
¼ HLzHT
¼
h
IðTÞ5

Dr  nc
n
Dp
Ti
½Sz5F
h
IðTÞ5

Dr  nc
n
Dp
i
¼
h
Dr  nc
n
Dp
T
F

Dr  nc
n
Dp
i
Sz:
(Equation 7)
To establish the relationship between the test statistic T2F for
general pedigrees and the T2 statistic for the population-based
association test, we need to simplify HZ. It is easy to see that

Dr  nc
n
Dp
T
Zt ¼
X
i˛ cases
Zti 
nc
n
Xn
i¼1
Zti
¼ ncZtA 
nc
n
h
ncZ
t
A þ ðn ncÞZ
t
G
i
¼ ncðn ncÞ
n
h
Z
t
A  Z
t
G
i
;
(Equation 8)
where Z
t
A and Z
t
G are averages of the indicator variables for the
genotypes at the tth variant site in cases and controls, respectively.
From Equation 8 it follows that
HZ ¼
h
IðTÞ5

Dr  nc
n
Dp
Ti
Z
¼ ncðn ncÞ
n
2
6664
Z
1
A  Z
1
G
«
Z
T
A  Z
T
G
3
7775:
(Equation 9)
Therefore, the test statistic T2F can be simplified to
T2F ¼
ðHZÞTS1z HZ
Dr  nc
n
Dp
T
F

Dr  nc
n
Dp

¼
	
ncðn ncÞ
n

2h
ðZA  ZGÞTS1z ðZA  ZGÞ
i

Dr  nc
n
Dp
T
F

Dr  nc
n
Dp

¼ T
2
n
ncðn ncÞ

Dr  nc
n
Dp
T
F

Dr  nc
n
Dp

¼ T
2
Pcorr
;
(Equation 10)
where T2 is the generalized T2 statistic for the population-
based association tests and Pcorr ¼ ðn=ncðn ncÞÞðDr  ðnc=nÞDpÞT
FðDr  ðnc=nÞDpÞ is the correction factor to be applied to the1030 The American Journal of Human Genetics 90, 1028–1045, Junegeneralized T2 statistic to have a valid test in the presence of pedi-
gree structures. The correction factor depends on kinship coeffi-
cients and the number of affected and unaffected individuals.
Under the null hypothesis of no association of the genomic region
with the disease, T2F is distributed as a central c
2
ðTÞ distribution with
T degrees of freedom.
CMC Test for Families
Now we extend the population-based CMC test to the families
with known or unknown population structure. We previously
extended the population-based generalized T2 test to the families.
Combining the collapsing test and the generalized T2 test for fami-
lies, we can obtain the CMC test for families in the samples. Specif-
ically, suppose that T variants can be classified as k groups of rare
variants and m individual variant sites.
Define indicator variables for the k group of rare variants:
vsi ¼
8<
:
1 presence of rare variants in the s-th group
of the i-th individual
0 otherwise;
s¼ 1..,k, and Ps¼ P(presence of the rare variants in the s - th group).
The variance of the indicator variable can be estimated by
s2s ¼ Psð1 PsÞ; s ¼ 1;2;.; k:
Let
Vs ¼
2
64
vs1
«
vsn
3
75 and V ¼
2
64V
1
«
Vk
3
75:
Define
h ¼
	
V
Z


and HCMC ¼ IðkþmÞ5

Dr  nc
n
Dp
T
;
where the parameters in the above equations are defined as before.
The vector h consists of two parts: one is for collapsed variants and
other one is for uncollapsed variants.
We define a diagonal matrix:
Sv ¼ diag

s21;s
2
2;.;s
2
k

: (Equation 11)
The covariance matrix is given by (Y.Y. Shugart, Y.Z., W. Guo,
and M.X., unpublished data)
Lv ¼ covðV ;VÞ ¼ Sv5F: (Equation 12)Thus, the covariance matrix of h is given by
L ¼
	
Sv Svz
Szv Sz


5F ¼ S5F; (Equation 13)
where
S ¼
	
Sv Svz
Szv Sz


:
Then, by the similar argument as before, the covariance matrix
of HCMCh is given by
GCMC ¼

Dr  nc
n
Dp
T
F

Dr  nc
n
Dp

S: (Equation 14)8, 2012
Thus, the family-based CMC statistic can be defined as
TCMCF ¼ ðHCMChÞTG1CMCHCMCh
¼ ðHCMChÞ
T
S1CMCHCMCh
Dr  nc
n
Dp
T
F

Dr  nc
n
Dp

¼
ncðn ncÞ
n
h
ðVA  VGÞTS1v ðVA  VGÞ þ ðZA  ZGÞTS1z ðZA  ZGÞ
i
ncðn ncÞ
n

Dr  nc
n
Dp
T
F

Dr  nc
n
Dp

¼ TCMC
Pcorr
;
(Equation 15)
where VA;VG are the averages of the indicator variables in cases
and controls, respectively; TCMC is the CMC statistic for the popu-
lation-based association test; and the correction factor Pcorr is
defined as before. The test statistic TCMCF follows a c
2
ðkþmÞ distribu-
tion with (k þ m) degrees of freedom, asymptotically, under the
null hypothesis of no association of the genomic region being
tested.The FPCA and Smoothed FPCA for Families
The FPCA and smoothed FPCA (SFPCA) can be applied to the pop-
ulation-based association studies.18 Now we extend them to
a general case where multiple families and additional population
structures are presented in the samples. Let bjðtÞ; j ¼ 1;2;.; k be
a set of eigenfunctions that are formed from the genotype data
of the sampled individuals under the SFPCA model. Let
xiðtÞ; i ¼ 1;2:;.;n be a genotypic function of the ith individual,
where t is the genomic position, and defined as
xiðtÞ ¼
8<
:
2 AtAt
1 Atat
0 atat
: (Equation 16)Suppose that the genotypic function xiðtÞ is expanded by eigen-
functions that are formed by the SFPCA as
xiðtÞ ¼
Xk
j¼1
xijbjðtÞ; (Equation 17)
where

bj;bl

l
¼
Z
T
bjðtÞblðtÞdt þ l
Z
T
€bjðtÞ€blðtÞdt ¼ 0
and xij ¼ hxi;bjil ¼
R
TxiðtÞbjðtÞdt þ l
R
T
€xiðtÞ€bjðtÞdt. l is a penalty
parameter, which is referred to as the smoothed functional-
component scores.When l is equal to zero, expansion of Equation
17 will be reduced to the FPCA expansion.
Our purpose is to use the functional principal-component scores
to develop test statistics that can be applied to pedigrees. To
achieve this, we first calculate the covariance matrix of the func-
tional principal-component scores. Let
x:j ¼

x1j; x2j;.; xnj
T
; xi: ¼ ½xi1; xi2;.; xikT and x ¼ ½x:1; x:2;.; x:kT :The AmericDefine
sxjk ¼ cov

x1j; x1k

¼ R
T
R
T
bjðsÞRðs; tÞbkðtÞdsdt þ l
R
T
R
T
bjðsÞ
v2Rðs; tÞ
vt2
€bkðtÞdsdt
þl R
T
R
T
€bjðsÞ
v2Rðs; tÞ
vs2
bkðtÞdsdt þ l2
Z
T
Z
T
€bjðsÞ
v4Rðs; tÞ
vs2vt2
€bkðtÞdsdt;
(Equation 18)
and
X
SFPCA
¼
2
666664
sx11 s
x
12 . s
x
1k
sx21 s
x
22 . s
x
2k
/ / / /
sxk1 s
x
k2 / s
x
kk
3
777775:
The matrix Sx can be estimated by
S^SFPCA ¼ 1
n k
Xn
i¼1
ðxi  xÞðxi  xÞT : (Equation 19)
Then, it can be shown that (Appendix B)
LSFPCAF ¼ covðx; xÞ
¼ P
SFPCA
5F:
(Equation 20)
Define
HFPCAF ¼ IðkÞ5

Dr  nc
n
Dp

(Equation 21)
and GSFPCA ¼ covðHFPCAFx;HFPCAFxÞ.
It follows from Equation 20 that
GSFPCA ¼
h
IðkÞ5

Dr  nc
n
Dp
Ti
LSFPCA
h
IðkÞ5

Dr  nc
n
Dp
i
¼
h
Dr  nc
n
Dp
T
F

Dr  nc
n
Dp
i
SSFPCA:
(Equation 22)
The family-based SFPCA statistic is then defined as
TSFPCAF ¼ ðHFPCAxÞTG1SFPCAHFPCAx: (Equation 23)
When l ¼ 0, the family-based SFPCA statistic TSFPCAF in Equa-
tion 23 is reduced to the family-based FPCA statistic without
smoothing.
Let xA and xG be the vector of averages of the functional prin-
cipal-component scores in cases and controls, respectively. It can
be show that the statistic TSFPCAF can be simplified to (Appendix B)
TSFPCAF ¼
	
ncðn ncÞ
n

2
ðxA  xGÞTS1SFPCAðxA  xGÞ
Dr  nc
n
Dp
T
F

Dr  nc
n
Dp

¼ TSFPCA
Pcorr
;
(Equation 24)
where TSFPCA is the population-based SFPCA statistic (L. Luo, Y.Z.,
and M.X., unpublished data) and Pcorr is the correction factor as
defined previously.
When penalty parameter l is equal to zero, the family-based
SFPCA TSFPCAF is reduced to the family-based FPCA statistic:
TFPCAF ¼ TFPCA
Pcorr
: (Equation 25)an Journal of Human Genetics 90, 1028–1045, June 8, 2012 1031
Table 1. Type I Error Rates of Five Statistics for the First Study
Design
Nominal Level 0.05 0.01 0.001
Theoretical Kinship Coefficient
c2 0.0349 0.0074 0.0006
CMC 0.0397 0.0082 0.0006
T2 0.0363 0.0078 0.0008
FPCA 0.0413 0.0086 0.0008
SFPCA 0.0413 0.0091 0.0008
Estimated Kinship Coefficient
c2 0.0364 0.0072 0.0006
CMC 0.0388 0.0084 0.0006
T2 0.0368 0.0078 0.0008
FPCA 0.0414 0.0088 0.0008
SFPCA 0.0426 0.0092 0.0008
Theoretical þ Estimated Coefficient
c2 0.0563 0.0124 0.0015
CMC 0.0591 0.0109 0.0009
T2 0.0719 0.0105 0.0017
FPCA 0.0857 0.0180 0.0010
SFPCA 0.0803 0.0135 0.0018
c2, individual c2 test; CMC, combined multivariate and collapsing method; T2,
generalized T2 test; FPCA, functional principal-component analysis; SFPCA,
smoothed FPCA.Under the null hypothesis of no association of the genomic
region, the statistics TSFPCAF and TFPCAF will be asymptotically
distributed as a central c2ðkÞ distribution where k is the number of
functional principal components in the eigenequation expansion
of genotypic functions.
Estimation of Kinship Matrix
All previous covariance matrices involve the kinship matrix.
Although the genealogical relationship between individuals in
the same pedigrees can be directly specified, the relationships
between individuals in the different pedigrees are usually
unknown. Given the presence of hidden population substructures
and cryptic relatedness in the samples, the genealogical relation-
ships between individuals in the different pedigrees cannot be
ignored. The kinship matrix includes both the pedigree relation-
ships of the related individuals and of the population structures.
In general, the kinship matrix F is unknown and can be estimated
by the genetic variants in the data. Consider mmarkers. Let xij be
the indicator variable for the jth SNP of the ith individual, as
defined before, and pi be the frequency of its reference allele.
The genealogical matrix can be estimated by19
fij ¼
1
m
Xm
k¼1
ðxik  2pkÞ

xjk  2pk

2pkð1 pkÞ ; isj
fii ¼ 1þ
1
m
Xm
k¼1
x2ik  ð1þ 2pkÞxk þ 2p2k
2pkð1 pkÞ ; i ¼ j:
(Equation 26)
Because the allele frequencies are unknown, they are estimated
as follows:16
Step 1 (initial): use the average allele frequency in the popula-
tion as bp to estimate F0;
Step 2 (iteration): let t be the tth SNP in the genomic region. For
the ith iteration, we
d use Fi to estimate bpi, bpti ¼ ð1TF1i 1Þ11TF1i Zt , where 1 is
a vector of 1 and Zt is a vector of indicator variable for the
genotypes at the tth SNP in the genomic region, as defined
before;
d use this bpi to estimate Fiþ1; and
d stop upon convergence or the meeting of maximum itera-
tion limits.
Results
Null Distribution of Test Statistics
To assess the type I error rates of the test statistics and the
impact of the use of known and estimated kinship coeffi-
cients on the family-based association studies, we per-
formed a series of simulation studies. We used the software
ForSim20 to simulate three different design settings. In the
first sitting, we sampled 40 outbred pedigrees that have
three generations, each pedigree having approximately
17 individuals, and 60 pedigrees that have two genera-
tions, each pedigree having approximately five individ-
uals, from a homozygous population. In each pedigree,
roughly half of the individuals were randomly labeled
as affected individuals; the remaining individuals were
assigned as unaffected. The second setting was similar to
the first, except that 70% of the pedigrees were sampled
from subpopulation 1 and the remaining 30% of the1032 The American Journal of Human Genetics 90, 1028–1045, Junepedigrees were sampled from subpopulation 2. Two
subpopulations were generated by dividing a population
into two subpopulations through phenotypic selection at
the fifth generation (The total number of generations in
the simulations was 100). The phenotype of an individual
was determined by natural selection. In subpopulation 1
we selected individuals within 0.4 SD of the mean pheno-
type, and in subpopulation 2 we selected individuals
within 0.6 SD of the mean phenotype. Two subpopula-
tions were then evolved in 95 generations via population
genetics models. The third setting was also similar to the
first, with the difference of the inclusion of an additional
500 unrelated cases and 500 unrelated controls in the
study. In all three settings, each individual had 168 rare
variants with minor allele frequencies (MAF) less than
0.01. A total of 5,000 simulations were repeated.
Tables 1, 2, and 3 summarize the type I error rates of the
five statistics: the SFPCA statistic, the FPCA statistic, the
CMC method,9 the generalized T2,17 and the corrected
individual c2 test (where we averaged the type I error rates
of multiple variants) for the first, second, and third study
designs, respectively. We considered three scenarios for
relatedness of individuals. For the first scenario, we used
theoretical kinship coefficients between pairs of individ-
uals in the same pedigrees as our kinship coefficients and8, 2012
Table 2. Type I Error Rates of Five Statistics for the Second Study
Design
Nominal Level 0.05 0.01 0.001
Theoretical Kinship Coefficient
c2 0.0365 0.0070 0.0006
CMC 0.0375 0.0087 0.0006
T2 0.0389 0.0083 0.0008
FPCA 0.0423 0.0091 0.0008
SFPCA 0.0428 0.0099 0.0008
Estimated Kinship Coefficient
c2 0.0389 0.0075 0.0006
CMC 0.0390 0.0092 0.0006
T2 0.0402 0.0086 0.0008
FPCA 0.0434 0.0095 0.0008
SFPCA 0.0438 0.0100 0.0008
Theoretical þ Estimated Coefficient
c2 0.0573 0.0103 0.0008
CMC 0.0553 0.0141 0.0006
T2 0.0554 0.0114 0.0012
FPCA 0.0667 0.0102 0.0008
SFPCA 0.0618 0.0118 0.0008
c2, individual c2 test; CMC, combined multivariate and collapsing method; T2,
generalized T2 test; FPCA, functional principal-component analysis; SFPCA,
smoothed FPCA.
Table 3. Type I Error Rates of Five Statistics for the Third Study
Design
Nominal Level 0.05 0.01 0.001
Theoretical Kinship Coefficient
c2 0.0344 0.0073 0.0007
CMC 0.0390 0.0096 0.0006
T2 0.0382 0.0096 0.0009
FPCA 0.0454 0.0118 0.0008
SFPCA 0.0475 0.0122 0.0008
Estimated Kinship Coefficient
c2 0.0343 0.0070 0.0006
CMC 0.0347 0.0083 0.0006
T2 0.0395 0.0081 0.0008
FPCA 0.0412 0.0095 0.0007
SFPCA 0.0418 0.0099 0.0008
Theoretical þ Estimated Coefficient
c2 0.0348 0.0074 0.0007
CMC 0.0406 0.0097 0.0006
T2 0.0370 0.0089 0.0009
FPCA 0.0445 0.0123 0.0008
SFPCA 0.0458 0.0118 0.0009
c2, individual c2 test; CMC, combined multivariate and collapsing method; T2,
generalized T2 test; FPCA, functional principal-component analysis; SFPCA,
smoothed FPCA.assumed that kinship coefficients between pairs of individ-
uals in differing pedigrees were zero. For the second
scenario, we assumed that individuals between different
pedigrees were related. The theoretical kinship coefficients
were again taken as our kinship coefficients between pairs
of individuals in the same pedigrees, and the kinship coef-
ficients between pairs of individuals in differing pedigrees
were estimated by the typed SNPs. For the third scenario,
we estimated all kinship coefficients between pairs of indi-
viduals by the typed SNPs, regardless of whether the paired
individuals were in the same or in differing pedigrees.
Tables 1, 2, and 3 show that the empirical type I error rates
of the test statistics were close to each other, whether we
use all theoretical kinship coefficients or all estimated
kinship coefficients in all three study designs. In this
case, the type I error rates of the SFPCA and FPCA statistics
were not significantly deviated from the nominal levels,
although they are slightly deflated at the significance level
a ¼ 0:05: In contrast, type I errors of the other statistics
were more deflated than the SFPCA and FPCA statistics.
Tables 1 and 2 also show that we found this result when
taking theoretical kinship coefficients between pairs of
individuals in the same pedigree as our kinship coefficients
and estimating the kinship coefficients between pairs of
individuals in the different pedigrees. Type I error rates of
all test statistics deviated significantly from the nominalThe Americlevels (inflated at the significance level a ¼ 0:05) for the
first and second study designs, and the statistics of the
individual c2 test, FPCA, and SFPCA also showed inflated
type I error rates at the significance level a ¼ 0:01 for the
first study design. The reason for this is as follows. The
estimated kinship coefficients depend on the selected
markers. In general, the estimated kinship coefficients
will not be equal to the theoretical kinship coefficients.
In our experience, the estimated kinship coefficients are
often smaller than the theoretical kinship coefficients.
Approximately, the estimated kinship coefficients are
equal to the theoretical kinship coefficients multiplied by
a constant. Let PEcorr and P
T
corr be the correction factors that
are obtained by the estimated and theoretical kinship coef-
ficients, respectively. Thus, we have PEcorr ¼ aPTcorr , which
implies that T2FðEÞ ¼ ð1=aÞT2FðTÞ, where T2FðEÞ and T2FðTÞ are
the test statistics based on the estimated and theoretical
kinship coefficients, respectively. The empirical distribu-
tion of the test statistic based on the estimated kinship
coefficients in simulations will be shifted by a constant
from the empirical distribution of the test statistic based
on theoretical kinship coefficients in the simulations.
Therefore, the type I error rates of both statistics will be
the same. However, when the theoretical kinship coeffi-
cients are used to measure the genetic relationships among
individuals in the same pedigrees and the estimatedan Journal of Human Genetics 90, 1028–1045, June 8, 2012 1033
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A B Figure 1. Power Curves of the Family-BasedCMC and Single-Marker Statistics as a Function
of Sample Size
(A) The power curves of the family-based CMC
(variants with frequencies % 0.005 were
collapsed) statistic as a function of the total
number of individuals at the significance level
a ¼ 0:05 in the test under seven settings: unre-
lated individuals in cases-controls study, nuclear
family groups 1 and 2, sib-pair groups 1 and 2,
and three-generational family groups 1 and 2,
assuming the dominant model, 20% of the risk
variants, and a baseline penetrance of 0.01.
(B) The power curves of the corrected single-
marker statistic as a function of the total number
of individuals at the significance level a ¼ 0:05
in the test under seven settings: unrelated
individuals in cases-controls study, nuclear
family groups 1 and 2, sib-pair groups 1 and 2,
and three-generational family groups 1 and 2,
assuming the dominant model, 20% of the risk
variants, and a baseline penetrance of 0.01.kinship coefficients are used to measure the genetic rela-
tionships among individuals in differing pedigrees,
because the genotypes of individuals in each simulation
will be changed, the correction coefficient that is depen-
dent on the simulations will change in complicated way,
which in turn will affect the empirical distribution of the
test statistics and type I error rates.
Power Evaluation
To evaluate the performance of the proposed statistics for
testing the association of variants, we used simulated
data to estimate their power to detect true associations.
We used the software ForSim20 to simulate pedigrees.
Each individual in the pedigree had 189 variant sites; the
MAF of all sites was less than 0.01, but more than 0.0001.
An individual’s disease status was determined on the
basis of the individual’s genotype and its penetrance at
each locus. Let Ai be a rare risk allele at the i
th variant
site. Let Gkiðk ¼ 0;1;2Þ be the genotypes aiai, Aiai, and
AiAi, respectively, and let fki be the penetrance of geno-
types Gki at the i
th locus. The relative risk (RR) at the ith
variant site is defined as R1i ¼ f1i=f0i and R2i ¼ f2i=f0i, where
f0i is the baseline penetrance of the wild-type genotype at
the ith variant site.We assumed that for the additive disease
model, R2i ¼ 2R1i  1; for the dominant disease model,
R2i ¼ R1i; for the recessive disease model, R1i ¼ 1; and for
the multiplicative disease model, R2i ¼ R21i. The genotype
RR was assumed to be inversely proportional to the MAF,
where the population attributable risk of each group was
assumed to be 0.006.21We assumed that the baseline pene-
trance of the wild-type genotype was equal across all
variant sites and that the variants influenced disease
susceptibility independently (i.e., without epistasis). We
considered four disease models: additive, dominant, reces-
sive, and multiplicative. Due to space limitation, we only1034 The American Journal of Human Genetics 90, 1028–1045, Junepresent the power of the tests under the dominant disease
models. However, the pattern of power of the tests under
other disease models will be mentioned. The disease status
of an individual in the pedigree was randomly assigned
according to the disease models. The process of sampling
required pedigrees from the population of pedigrees was
repeated until the desired pedigrees were obtained for
each disease model.
We considered three family structures: nuclear family
with two parents and two offspring, sibling pair (sib-
pair), and three-generational family (each family with
about 20 individuals). We further divided the nuclear fami-
lies into nuclear family 1, in which we considered one
affected parent and one affected offspring, and nuclear
family 2, in which we considered one affected parent and
two affected offspring. Sib-pairs were also divided into
two groups. Sib-pair 1 consisted of one affected sibling
and one unaffected sibling. In sib-pair 2, we considered
a total of 2/3 of the sib-pairs with two affected siblings
and 1/3 of the sib-pairs with one affected sibling and one
unaffected sibling. Again, three-generational families
were also divided into two subgroups. In group 1, we
assume that each family had an equal number of affected
and unaffected individuals. In group 2, 2/3 of the
individuals in each family were affected, and 1/3 of
the individuals in each family were unaffected. To study
the sensitivity of the developed methods to the number
of affected individuals, we considered three-generational
family group 3, wherein only 1/3 of individuals were
affected. We assumed that the total number of individuals
in each family structure was approximately equal. Power
calculations were performed by simulations. For each
case, 2,000 simulated replicates were performed.
Figures 1 and 2 show the power curves of the family-
based CMC (variants with frequencies % 0.005 were8, 2012
900 1200 1500 1800 2100
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Number of Sampled Individuals
Po
w
er
SFPCA, Dominant
Unrelated
Nuclear Family 1
Nuclear Family 2
Sib−Pair 1
Sib−Pair 2
Three Generations 1
Three Generations 2
900 1200 1500 1800 2100
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Number of Sampled Individuals
Po
w
er
FPCA, DominantA B Figure 2. Power Curves of the Family-Based
FPCA and SFPCA Statistics as a Function of
Sample Size
(A) The power curves of the family-based FPCA
statistic as a function of the total number of indi-
viduals at the significance level a ¼ 0:05 in the
test under seven settings: unrelated individuals
in cases-controls study, nuclear family groups 1
and 2, sib-pair groups 1 and 2, and three-genera-
tional family groups 1 and 2, assuming the domi-
nant model, 20% of the risk variants and a base-
line penetrance of 0.01.
(B) The power curves of the family-based SFPCA
statistic as a function of the total number of indi-
viduals at the significance level a ¼ 0:05 in the
test under seven settings: unrelated individuals
in cases-controls study, nuclear family groups 1
and 2, sib-pair groups 1 and 2, and three-genera-
tional family groups 1 and 2, assuming the
dominant model, 20% of the risk variants, and
a baseline penetrance of 0.01.collapsed), FPCA, SFPCA, and the corrected single-marker
c2 statistics as a function of the total number of individuals
in the test, at the significance level a ¼ 0:05 and under
seven settings: unrelated individuals in cases-controls
study, nuclear family groups 1 and 2, sib-pair groups 1 and
2, and three-generational family groups 1 and 2, with the
assumption of a homogeneous population, the dominant
model, 20% of risk variants, and a baseline penetrance of
0.01. Several remarkable features emerged from these
results. First, as expected, in general, family-based associa-
tion studies had much higher power than population-
based association studies. Particularly, the corrected
single-marker c2 test, wherein permutation was used to
adjust formultiple testing, is designed to adapt the standard
c2 test for accounting for relatedness among in-
dividuals.13,14 The corrected single-marker c2 test is a tradi-
tional linkage- and association-analysis method without
defined pedigrees. The corrected single-marker c2 test also
clearly demonstrated that family-based association tests
had a higher power than population-based association tests
(Figure 1B). Second, when the pedigrees have more com-
plex structures, the rare risk variants will be more enriched
in the pedigrees; therefore, such pedigrees will provide
more information of coinheritance of rare risk variants
with diseases in families, and hence, they will have more
power to detect associations. Third, we also observed that
the three-generational family group2, nuclear family group
2, and sib-pair group 2 had higher power than the corre-
sponding three-generational family group 1, nuclear family
group 1, and sib-pair group 1, where each family in group 2
had more affected individuals than in group 1. We also
observed the same patterns in Figures 3 and 4, which
show the power of four statistics as a function of the propor-
tion of risk variants, assuming 1,800 sampled individuals.
To compare the power of five family-based statistics,
SFPCA, FPCA, CMC, the generalized T2, and the single-The Americmarker c2, wherein we used permutation to adjust for
multiple testing of three family structures, we present
Figures 5 and 6, which show the power curves of five statis-
tics as a function of the total number of sampled individ-
uals in the pedigrees for three-generational family group
1, sib-pair group 1, nuclear family group 1 and three-gener-
ational family group 3 that has 1/3 affected individuals in
its pedigrees. The power of the five statistics for the three-
generational family group 2, sib-pair group 2, nuclear
family group 2, and unrelated individuals are shown in
Figures S1–S4 (available online), respectively. From these
results, we observed that the family-based SFPCA had the
highest power for any family structure and sample size.
We also observed that the corrected single-marker c2 test
had the lowest power in all settings. This demonstrates
that, similar to population-based association studies, the
classical variant-by-variant paradigm of linkage and associ-
ation analysis designed for common variants may also
have low power to test the association of rare variants in
family-based association studies.
To study the sensitivity of these methods to the number
of affected individuals, we performed simulations for
three-generational family group 3 (wherein only 1/3 of
individuals in the family were affected). The results are
shown in Figure 6B. Although the power of the test statis-
tics was reduced, the power pattern of all statistics did not
change. This is also true for other types of families (data
not shown).
Next, we studied the impact of the proportion of risk
variants on the power. Figures 7 and 8A show the power
curves of five statistics, SFPCA, FPCA, CMC, the general-
ized T2, and the corrected single-marker c2, as a function
of the proportion of risk-increasing variants for testing
the association of 189 rare variants with disease, under
the dominant disease model and at the significance level
a ¼ 0:05, for three-generational family group 1, sib-pairan Journal of Human Genetics 90, 1028–1045, June 8, 2012 1035
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CMC, DominantA B Figure 3. Power of Family-Based CMC and
Single-Marker Statistics as a Function of the
Proportion of Risk Variants
(A) The power curves of the family-based CMC
(variants with frequencies % 0.005 were
collapsed) statistic as a function of the propor-
tion of risk variants at the significance level
a ¼ 0:05 in the test under seven settings: unre-
lated individuals in cases-controls study,
nuclear family groups 1 and 2, sib-pair groups
1 and 2, and three-generational family groups
1 and 2, assuming the dominantmodel, a total
of 1,800 sampled individuals, and a baseline
penetrance of 0.01.
(B) The power curves of the corrected single-
marker statistic as a function of the proportion
of rare variants at the significance level
a ¼ 0:05 in the test under seven settings: unre-
lated individuals in cases-controls study,
nuclear family groups 1 and 2, sib-pair groups
1 and 2, and three-generational family groups
1 and 2, assuming the dominantmodel, a total
of 1,800 sampled individuals, and a baseline
penetrance of 0.01.group 1, and nuclear family group 1 with 1,800 individuals
assigned as affected and 1,800 individuals assigned as unaf-
fected. The power of five statistics for the three-genera-
tional family group 2, sib-pair group 2, nuclear family
group 2, and unrelated individuals are shown in Figures
S5–S8, respectively. Similar to data shown in Figures 5, 6,
and S1–S4, we observed that the family-based SFPCA had
the highest power in every situation considered. We also
observed that power differences between the SFPCA
statistic and the corrected single-marker c2 test were
much larger than those between the CMC method and
the corrected single-marker c2 test. The difference in power
between the newly developed statistics such as FPCA and
CMC, originally designed for testing association of rare0.1 0.15 0.2
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1036 The American Journal of Human Genetics 90, 1028–1045, Junevariants, and the corrected single-marker c2 test, originally
proposed for testing association of common variants in
population-based association studies, tends to become
larger as the proportion of risk variants increases in
family-based association studies, in general.
To study how the distribution of variants affects the
power, we plotted Figure 8B, which shows the power as
a function of the ratio of the number of rare risk variants
over the number of common risk variants for three-gener-
ational family group 2, wherein 1,500 individuals were
sampled. Figure 8B shows that as the ratio of the number
of rare risk variants over the number of common risk vari-
ants increases, the power of tests will increase. This shows
that the contribution of rare variants is larger than that of0.25 0.3
Variants
nant
ted
air 1
air 2
r Family 1
r Family 2
 Generations 1
 Generations 2
Figure 4. Power Curves of Family-Based FPCA
and SFPCA Statistics as a Function of the Propor-
tion of Risk Variants
(A) The power curves of the family-based FPCA
statistic as a function of the proportion of risk
variants at the significance level a ¼ 0:05 in the
test under seven settings: unrelated individuals
in cases-controls study, nuclear family groups 1
and 2, sib-pair groups 1 and 2, and three-genera-
tional family groups 1 and 2, assuming the domi-
nant model, a total of 1,800 sampled individuals,
and a baseline penetrance of 0.01.
(B) The power curves of the family-based SFPCA
statistic as a function of the proportion of rare
variants at the significance level a ¼ 0:05 in the
test under seven settings: unrelated individuals
in cases-controls study, nuclear family groups 1
and 2, sib-pair groups 1 and 2, and three-genera-
tional family groups 1 and 2, assuming the domi-
nant model, a total of 1,800 sampled individuals,
and a baseline penetrance of 0.01.
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Sample Sizes for Group 1 Three-Generational
Family and Sib-Pair
(A) The power curve of five family-based statistics:
SFPCA, FPCA, CMC, generalized T2, and indi-
vidual c2 statistic for three-generational family
group 1 as a function of the total number of indi-
viduals at the significance level a ¼ 0:05 under
the dominant model, assuming 20% of risk vari-
ants and a baseline penetrance of 0.01.
(B) The power curve of five family-based statistics:
S FPCA, FPCA, CMC, generalized T2, and indi-
vidual c2 statistic for sib-pair group 1 as a function
of the total number of individuals at the signifi-
cance level a ¼ 0:05 under the dominant model,
assuming 20% of risk variants and a baseline
penetrance of 0.01.common variants. This power pattern will hold for other
scenarios.
To examine the impact of the direction of the association
of rare alleles with disease risk on the power of the tests, we
assumed that the genomic region being tested included
both risk and protective variants. We randomly selected
10% of the variants as risk variants and 10% of the variants
as protective variants. Figure 9 shows the power curves of
the five statistics, S FPCA, FPCA, CMC, the generalized T2,
and the corrected single-marker c2, for three-generational
family group 2, under the dominant model and at the
significance level a ¼ 0:05, as a function of the total
number of sampled individuals in the pedigrees. The power
patterns of the five statistics for testing association of rare
variants for other family structures were similar (data not900 1200 1500 1800 2100
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The American Journal of Hushown). These results clearly demonstrated
that thepower of the SFPCAwas thehighest,
followed by the classical nonsmooth FPCA.
We also observed that as sample size
increases, the SFPCA and FPCA statisticswere less sensitive to the direction of the association of
rare alleles than were other statistics.
Application to a Real Data Example
For further evaluation of their performance, five family-
based association test statistics were applied to the FHS
for cardiovascular disease (CVD) that includes coronary
heart disease, stroke, heart failure, and atrial fibrillation.
FHS is a prospective epidemiological cohort study estab-
lished in 1948 and designed to evaluate risk factors for
CVD. A total of 5,226 individuals were genotyped with
the Affymetrix GeneChip Human Mapping 500K Array-
Set.We included 1,603 individuals (267 individuals with
CVD and 1,336 controls) from 462 pedigrees in our
analysis.22 The data were downloaded from dbGAP. WeFigure 6. Power of Tests as a Function of
Sample Sizes for Group 1 Nuclear Family and
Group 2 Three-Generational Family
(A) The power curve of five family-based statistics:
SFPCA, FPCA, CMC, generalized T2, and indi-
vidual c2 statistic for nuclear family group 1 as
a function of the total number of individuals at
the significance level a ¼ 0:05 under the domi-
nant model, assuming 20% of risk variants and
a baseline penetrance of 0.01.
(B) The power curve of five family-based statistics:
SFPCA, FPCA, CMC, generalized T2, and indi-
vidual c2 statistic for the three-generational
family group 3 as a function of the number of
sampled individuals at the significance level
a ¼ 0:05 under the dominant model, assuming
20% of risk variants and a baseline penetrance
of 0.01.
man Genetics 90, 1028–1045, June 8, 2012 1037
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Figure 7. Power of Tests as a Function of the
Proportion of Risk Variants for Group 1 Three-
Generational Family and Sib-Pair
(A) The power curve of five family-based statistics:
SFPCA, FPCA, CMC, generalized T2, and indi-
vidual c2 statistic for the three-generational
family group 1 as a function of the proportion
of risk variants at the significance level a ¼ 0:05
under the dominant model, assuming a total of
1,800 sampled individuals and a baseline pene-
trance of 0.01.
(B) The power curve of five family-based statistics:
SFPCA, FPCA, CMC, generalized T2, and indi-
vidual c2 statistic for sib-pair group 1 as a function
of the proportion of risk variants at the signifi-
cance level a ¼ 0:05 under the dominant model,
assuming a total of 1,800 sampled individuals
and a baseline penetrance of 0.01.analyzed the association of genes with at least three SNPs
with a MAF of less than 0.05. A total of 2,913 genes with
29,756 SNPs were analyzed. The p value for declaring asso-
ciation after Bonferroni correction was 1:723105 for
multiple tests. The results of five family-based association
tests, wherein the p value for the corrected single-marker
c2 statistic was obtained by permutation, are summarized
in Table 4. We found that four genes reached genome-
wide significance (1:723105) with the SFPCA test. Table 4
shows that the SFPCA statistic had the lowest p values
among the five tests, followed by the FPCA test statistic.
It is also noted that each gene in Table 4 had at least one
SNP with a small p value, but the SFPCA and FPCA tests
that combine the single-marker test with the group test.2.5 1 5
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1038 The American Journal of Human Genetics 90, 1028–1045, June 8, 2012had a smaller p value than the single-
marker test with correction for multiple
tests. To further reveal the relationships
between the structure of rare variantswithin the gene and the SFPCA test, we present
Figure S9, which shows the LD pattern of nine rare variants
within the gene CRY1 and their p values from individual
tests for the association of a single SNP with disease by
the family-based corrected single-marker c2 test. Seven of
these nine SNPs showed mild significance and formed
two haplotype blocks with strong LD. The strong LD
among the seven SNPs may imply that these variants are
of recent origin. CRY1 is a circadian gene and is involved
in breast cancer23 and chronic lymphocytic leukemia.24
NOX3 contributes to coronary endothelial dysfunction in
the failing heart25 and is involved in inflammation.26
BOMB is associated with signals for lipids and apolipopro-
teins,27 and MRPS18C helps with protein synthesis withinFigure 8. Power of Tests for the Proportion of
Risk Variants for Group 1 Nuclear Family and
Group 2 Three-Generational Family
(A) The power curve of five family-based statistics:
SFPCA, FPCA, CMC, generalized T2, and indi-
vidual c2 statistic for nuclear family group 1 as
a function of the proportion of risk variants at
the significance level a ¼ 0:05 under the domi-
nant model, assuming a total of 1,800 sampled
individuals and a baseline penetrance of 0.01.
(B) The power curve of five family-based statistics:
SFPCA, FPCA, CMC, generalized T2, and indi-
vidual c2 statistic for three-generational family
group 2 as a function of the ratio of the number
of rare risk variants over the number of common
risk variants at the significance level under the
dominant model, assuming a total of 1,500
sampled individuals and a baseline penetrance
of 0.01.
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Figure 9. Power Comparison of Tests for Group 2 Three-
Generational Family under Opposite Directions of Association
The power comparison of five family-based statistics: SFPCA,
FPCA, CMC, generalized T2, and individual c2 statistic for three-
generational family group 2 under opposite directions of associa-
tion as a function of the total number of individuals at the signif-
icance level a ¼ 0:05 under the dominantmodel, assuming 20%of
the risk variants in one direction of association, 10% of risk vari-
ants and 10% of protective variants in two opposite directions of
association, and a baseline penetrance of 0.01.the mitochondrion and is involved in AIDS progression.28
FAM175A is involved in DNA repair29 and is a new candi-
date breast cancer-susceptibility gene.30
For illustration of the application of the family-based
association tests for common variants, the proposed statis-
tics were applied to childhood-onset asthma studies.31 A
total of 206 nuclear families (MRC-A), which included
285 sib-pairs, seven half sib-pairs, and three singletons
(counting all possible siblings), 420 individuals with
childhood asthma, and 428 unaffected individuals, were
sampled through a proband with severe childhood-onset
asthma (data were kindly provided by Dr. Liming Liang,Table 4. p Values of Five Family-Based Statistics for Testing Associati
Gene
Number
of SNPs
p Value
SFPCA FPCA CMC
CRY1 10 1.20 3 1005 1.29 3 1004 3.77 3
NOX3 5 1.25 3 1005 1.60 3 1004 2.38 3
BOMB 5 1.60 3 1005 2.07 3 1003 2.26 3
MRPS18C 12 1.70 3 1005 2.08 3 1003 3.52 3
FAM175A 9 1.93 3 1005 1.93 3 1003 2.07 3
c2, individual c2 test; CMC, combined multivariate and collapsing method; T2
smoothed FPCA.
The AmericDepartment of Epidemiology and Biostatistics, Harvard
University). The parents and children in the MRC-A panel
were typed with the Illumina Sentrix Human-1 Genotyp-
ing 10K BeadChip. A total of ten SNPs with MAF R 0.18
in Table 1 of the Moffatt et al. paper31 were included in
this analysis. Table 5 summarizes p values of five family-
based statistics for testing the association of ORMDL3,
which harbors common variants with childhood-onset
asthma. Given that all SNPs in the analysis were common
variants, no SNPs in ORMDL3 should be grouped in the
CMC test. Therefore, p values for both the CMC method
and the T2 test were the same. Similar to in Table 4, we
also observed that the SFPCA statistic had the lowest
p values among the five tests, followed by the FPCA test
statistic. Four of ten SNPs showed significant association,
with all p values % 0.015, as assessed by a family-based
corrected single-marker c2 test (data not shown). The
association of ORMDL3 with childhood-onset asthma
was discovered in the MRC-A study and also confirmed
in an independent replication study.31 The association of
ORMDL3 was also supported by a gene expression study.
It was reported that the SNPs in ORMDL3 showed strong
association (p < 1022) in cis with expression levels of
ORMDL3.31Discussion
Association studies can be carried out either by case-
control studies of unrelated individuals or by family-based
designs. Both designs have their merits and limitations.
However, since it was demonstrated in 1996 that associa-
tion studies are often more powerful than linkage anal-
yses,32 population-based association studies have become
the current paradigm for the genetic studies of complex
diseases. In the past several years, several authors12,13,33
have challenged the current genetic-study practice that
takes population-based association analysis as the only
paradigm for genetic studies of complex diseases. There
have been an increasing number of debates regarding
which study design, population-based or family-based, is
the choice design for identifying association of rare vari-
ants. One of the purposes of this report is to address severalon with CVD
T2
Individual c2
(Permutation)
Individual c2
(Minimum)
1004 5.97 3 1004 1.00 3 1003 9.98 3 1005
1001 2.87 3 1004 3.00 3 1003 7.50 3 1004
1003 2.26 3 1003 1.00 3 1003 1.02 3 1003
1001 3.52 3 1001 5.00 3 1003 1.81 3 1003
1001 2.07 3 1001 4.00 3 1003 1.80 3 1003
, generalized T2 test; FPCA, functional principal-component analysis; SFPCA,
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Table 5. p Values of Five Family-Based Statistics for Testing the Association of ORMDL3 with Childhood-Onset Asthma
SFPCA FPCA CMC T2 Individual c2 (Permutation) Individual c2 (Minimum)
7.87 3 1007 4.39 3 1006 1.46 3 1003 1.46 3 1003 2.35 3 1002 1.37 3 1003
c2, individual c2 test; CMC, combined multivariate and collapsing method; T2, generalized T2 test; FPCA, functional principal-component analysis; SFPCA,
smoothed FPCA.issues in devising optimal strategies for association analysis
of rare variants.
The first issue is to develop a simple and general analyt-
ical framework that can unify both population-based and
family-based case-control association analysis. The tradi-
tional linkage-analysis methods, whether parametric or
nonparametric, are complex, difficult to collectively
analyze across multiple variants, and require intensive
computations. The current popular statistical methods
for population-based association studies are simple, but
often assume that the selected samples are independent.
Thus, these methods are unable to analyze correlated
family data with rare variants. Recently, case-control
association tests have been extended to include related
individuals from structured populations.16 Case-control
association testing with population and pedigree structure,
referred to herein as family-based case-control association
testing, can be applied to (1) an isolated population in
which individuals may be related, (2) an admixed popula-
tion, (3) pedigrees sampled with a single population, and
(4) pedigrees sampled from structured populations.
However, the recently developed family-based case-control
association analysis can test the association of a single
variant or of multiple unlinked variants. It is mainly
designed for testing association of common variants. To
overcome these limitations, we extend family-based case-
control association tests from a single variant to multiple
linked or unlinked variants. An essential element in the
family-based case-control association test statistics is calcu-
lation of the covariance matrix of genomic variants of the
related individuals. The current methods can only calcu-
late the covariance matrix of a single variant or multiple
unlinked variants of the related individuals. We derive
two new formulas to decompose the covariance matrix.
One decomposes the covariance matrix of multiple linked
variants of related individuals into the Kronecker product
of their corresponding covariancematrix of unrelated indi-
viduals and the kinship matrix of related individuals.
Another decomposes the covariance matrix of functional
principal-component scores that are derived from geno-
type profiles of related individuals into the Kronecker
product of their corresponding covariance matrix of the
functional principal-component scores generated from
unrelated individuals and the kinship matrix of the related
individuals. This lays down the foundation for developing
family-based statistics. Then, we extend the generalized T2
test and FPCA from independent samples to dependent
samples. In the presence of only unrelated individuals,
the kinship matrix becomes an identity matrix. Therefore,1040 The American Journal of Human Genetics 90, 1028–1045, Juneall statistics for population-based case-control association
studies are our special cases. We have successfully devel-
oped a general framework that can unify both popula-
tion-based and family-based case-control association tests.
The proposed methods can take the combination of data
from pedigrees with different relationship structure and
case-control samples from populations.
The second issue is to extend statistics for testing the
association of rare variants from the population-based
approach to the family-based approach. In the past several
years, a number of new population-based statistics for
testing the association of rare variants have been devel-
oped.We extend the generalizedT2 statistic, CMCmethod,
FPCA, and SFPCA statistics that are developed for popula-
tion samples to the pedigree data or mixed pedigree and
unrelated individual data sampled from the populations.
We show that statistics that compare differences in fre-
quencies of alleles, collapsed variables, or functional prin-
cipal-components scores between affected and unaffected
individuals in pedigrees can be decomposed into the
product of their corresponding statistics for population-
based association tests and correction factor that accounts
for pedigree and population structure. Thus, any popula-
tion-based statistics for association studies can be extended
to family-based association tests by multiplying their
statistics by a common correction factor that depends on
kinship coefficients and cryptic relatedness. This general
approach provides a bridge between population-based
association tests and family-based association tests.
The third issue is the validity of statistics for testing the
association of variants in the presence of pedigree struc-
ture. Using large simulations, we show that the type I error
rates of the FPCA and SFPCA statistics that use genotype
data to estimate the relatedness of individuals were not
significantly different from there nominal levels in the
presence of pedigree structures and population structures,
including admixed populations.
The fourth issue is the power of the tests and choice of
the designs. The challenge that arises from testing the asso-
ciation of rare variants is the power of the tests. Due to the
low frequency of rare variants, many statistics suffer from
low power of detection of the association of rare variants.
One strategy to improve the power of the tests is to enrich
rare variants in the samples. As we expected, the rare risk
variants are enriched in families. By using large simula-
tions, we show that, given an equal number of sampled
individuals, the family-based association studies have
a much higher power than the population-based associa-
tion studies for all statistics and in all settings. We also8, 2012
observe that the more complex the pedigree structure in
the samples, the higher the power for testing the associa-
tion of rare variants. The families with more affected indi-
viduals can provide more enrichment of rare risk variants
and gain more power to detect association. Another
remarkable feature of family-based association studies is
that unlike in population-based association studies where
the group tests will lose power if the opposite association
directions exist among the collapsed rare variants, the
simultaneous presence of risk and protective variants has
less impact on the power of the family-based association
tests.
The difficulties in identifying association of rare variants
and the high cost of sequencing samples illustrate the need
for more powerful statistical methods for detection of the
association of variants. By using simulations, we compare
the power of the corrected single-marker c2 test, CMC,
the generalized T2 statistic, the FPCA, and the SFPCA
statistics. We find that the SFPCA statistic had the highest
power among five compared statistics in any setting, and
the difference in power between the SFPCA statistic and
other test statistics increased as the proportion of risk vari-
ants or sample sizes increased. The results in this report are
quite preliminary. Due to space limitations, we have not
presented the type I error rates and power of the developed
statistics for testing the association of common variants or
both rare and common variants. In our simulations, the
empirical type I error rates of both smoothed and
unsmoothed FPCA are not significantly deviated from
nominal levels. Their power is still much higher than
that of other tests (data not shown).
The fifth issue is how to reduce the sequencing errors
and effectively deal withmissing value problems that often
arise from NGS. Given that the transmission pattern in
the pedigrees easily allows the correction of sequencing
errors, and the genotype data in other members of the
pedigrees provide useful information to infer the missing
genotypes of other individuals in the pedigrees, family-
based association studies provide a powerful tool to over-
come high sequencing-error rates and the problems with
large proportions of missing values inherent in NGS
technologies.
To demonstrate the feasibility of the family-based statis-
tics for testing the association of rare variants with the
disease, we apply the proposed methods to FHS and
childhood-onset asthma studies. Our results showed that
although variant-by-variant analysis could not identify
the rare variants that were significantly associated with
CVD, the family-based SFPCA identified five significantly
associated genes after Bonferroni correction for multiple
tests by collectively testing the association of multiple
rare variants with mild association within the gene.
However, the results presented need to be interpreted
with caution. The number of SNPs within a gene is small
due to poor coverage by microarray. To our knowledge,
results of the FHS 500 K project have never been published.
It is difficult to validate our findings, although five identi-The Americfied genes are biologically related with CVD according
to the reports in the literature.27 In childhood-onset
asthma studies, we confirmed the significant association
of ORMDL3, which harbors common variants related to
childhood-onset asthma. In the near future, exome- or
whole-genome-sequencing data with pedigrees are ex-
pected to become available, and evaluation of our methods
with sufficient sources will then be possible.
NGS has the potential to discover millions of rare vari-
ants and make it feasible to systematically search for the
entire allelic spectrum of genetic variants associated with
diseases. A great challenge raised by NGS is the develop-
ment of analytical methods and study designs with suffi-
cient power to identify association of variants with disease.
The methods presented here are simple extensions of pop-
ulation-based-association-test statistics to family-based
studies, on the basis of comparing differences in frequency
of alleles or collapsed alleles, or functional principal-
component scores. Other approaches to the extension of
population-based association tests to family-based tests,
such as the quasi-likelihood approach, may be more
powerful. However, the presented general framework that
can unify population-based and family-based association
analysis provides a platform to compare different study
designs. Computations of developed family-based associa-
tion tests are almost as simple as the population-based
association tests.
Recently, four Texas-based genome researchers8 pro-
posed a unified genetic model for human diseases. They
assumed that the common variants segregating within
a population arise from remote ancestors and the rare
variants segregating in the pedigree arise from recent ances-
tors. They hypothesized that genetic factors that cause
diseases include common variants, rare variants,mutations
inherent in the parents, and de novo variants. They also
broke down the artificial boundaries between categories
of human diseases and combined complex diseases,
Mendelian diseases, chromosomal syndromes, and geno-
mic disorders into one continuum disease model. The
unified genetic model requires integration of various
disease-risk variants in the population, pedigrees, and indi-
viduals. This raises a great analytical challenge for the use of
the unified genetic model to unravel the genetic architec-
ture of complex diseases. Our results in this report are
preliminary. Our intention is to stimulate further discus-
sion regarding the study designs and analytical methods
of association studies with next-generation-sequencing
data as well as the search for new analytical platforms
with which to use the unified genetic model for identifica-
tion of the genetic variants that underlie diseases.
Appendix A
Let
xti ¼

1 At
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We define yti similarly. Then, we have
zti ¼ xti þ yti ; t ¼ 1;2;.;m; i ¼ 1;2;.;n:
Define
stt ¼ 2PðAtÞð1 PðAtÞÞ; t ¼ 1;2:;.;m:
Let hi be the inbreeding coefficient of individual i and fij
be the kinship coefficient between individuals i and j:
Computing expectations by conditioning, we have
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:
(Equation A1)
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(Equation A2)
By definition of the covariance between variables
zti and z
t
j , we obtain
cov

zti ; z
t
j

¼ E
h
xti x
t
j þ xti ytj þ yti xtj þ yti ytj
i
 E
h
xti þ yti

xtj þ ytj
i
:
(Equation A3)
Substituting Equations A1 and A2 into Equation A3, we
obtain
cov

zti ; z
t
j

¼ 2fij
n
E
h
xti þ yti
2i Exti þ yti 2o
¼ 2fijstt :
(Equation A4)
Similarly, we have
cov

zti ; z
t
i
 ¼ ð1þ hiiÞstt : (Equation A5)
Combining Equations A4 and A5, we obtain
cov

Zt ;Zt
 ¼ sttF; (Equation A6)
where
F ¼
2
666664
ð1þ h1Þ 2f12 / 2f1n
2f21 1þ h2 / 2f2n
/ / / /
2fn1 2fn2 . 1þ hn
3
777775 (Equation A7)
Through a similar argument as that for Equation A4, we
have
cov

ztki ; z
tl
j

¼ 2fijstktl : (Equation A8)1042 The American Journal of Human Genetics 90, 1028–1045, JuneCombining Equations A6 and A8 leads to
Lz ¼ covðZ;ZÞ
¼
2
66664
covðZ1;Z1Þ covðZ1;Z2Þ / covðZ1;ZmÞ
covðZ2;Z1Þ covðZ2;Z2Þ / covðZ2;ZmÞ
/ / / /
covðZm;Z1Þ covðZm;Z1Þ / covðZm;ZmÞ
3
77775
¼ Sz5F;
(Equation A9)
where
X
z
¼
2
664
s11 s12 / s1m
s21 s22 / s2m
/ / / /
sm1 sm2 / smm
3
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First, we calculate covðxiðsÞ; xkðtÞÞ. Computing expectation
by conditioning, we obtain
covðxiðsÞ; xkðtÞÞ ¼ E½E½xiðsÞxkðtÞ j xiðtÞ
E½xiðsÞE½E½xkðtÞ j xiðtÞ
¼ 2fikE½xiðsÞxiðtÞ  2fikE½xiðsÞE½xiðtÞ
¼ 2fikRðs; tÞ;
(Equation B1)
where Rðs; tÞ is a covariance function of the genotype indi-
cator variables between genomic positions s and t.
Similarly, we have
cov

xiðsÞ; €xkðtÞ
 ¼ 2fikcovxiðsÞ; €xiðtÞ
¼ 2fik
v2Rðs; tÞ
vt2
;
(Equation B2)
cov

€xiðsÞ; xkðtÞ

¼ 2fik
v2Rðs; tÞ
vs2
; (Equation B3)
and
cov

€xiðsÞ; €xkðtÞ

¼ 2fik
v4Rðs; tÞ
vs2vt2
: (Equation B4)
From stochastic calculus,34 we can obtain
cov
0
@Z
T
x1ðtÞbjðtÞdt;
Z
T
x1ðtÞbkðtÞdt
1
A
¼
Z
T
Z
T
bjðsÞRðs; tÞbkðtÞdsdt;
(Equation B5A)
cov
0
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Z
T
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¼
Z
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(Equation B5B)8, 2012
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(Equation B5C)
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(Equation B5D)
Combining Equations B5A–B5D, we obtain the covari-
ance between functional principal-component scores for
the same individual without inbreeding:
sxjk ¼ cov
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x1j; x1k
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€bj ðtÞdsdt:
(Equation B6)
Using Equations B1–B4 and B6, we can obtain the covari-
ance of the functional principal-component scores
between a pair of individuals:
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;
¼ 2filsxjk: (Equation B7)
Similarly, considering inbreeding, we can prove that
var

xij
 ¼ ð1þ hiÞsxjj: (Equation B8)The AmericDefine the covariance matrix of the vector of functional
principal-component score x as
Lx ¼
2
666664
varðx:1Þ covðx:1; x:2Þ / covðx:1; x:kÞ
covðx:2; x:1Þ varðx:2Þ / covðx:2; x:kÞ
/ / / /
covðx:k; x:1Þ covðx:k; x:1Þ / varðx:kÞ
3
777775:
However, we have
var

x:j
 ¼ sxjjF (Equation B9)
and
cov

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 ¼ sxjkF: (Equation B10)
Let
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2
6666664
sx11 s
x
12 / s
x
1k
sx21 s
x
22 / s
x
2k
/ / / /
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7777775:Then, by combining Equations B9 and B10, we obtain
LSFPCA ¼ SSFPCA5F: (Equation B11)
Let
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Combining Equations B12, 22, and 23, we obtain
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Supplemental Data
Supplemental Data include nine figures and can be found with
this article online at http://www.cell.com/AJHG/.Acknowledgments
The project was supported by grants 1R01AR057120-01,
1R01HL106034-01, and 1U01HG005728-01 from the National
Institutes of Health. We thank the anonymous reviewers for their
helpful comments.
The Framingham Heart Study is conducted and supported by
the National Heart, Lung, and Blood Institute (NHLBI) in collabo-
ration with Boston University (contract no. N01-HC-25195). This
manuscript was not prepared in collaboration with investigators
of the Framingham Heart Study and does not necessarily reflect
the opinions or views of the Framingham Heart Study, Boston
University, or NHLBI. Funding for SNP Health Association
Resource (SHARe) genotyping was provided by NHLBI contract
N02-HL-64278.
Received: October 22, 2011
Revised: April 19, 2012
Accepted: April 28, 2012
Published online: June 7, 2012Web Resources
The URLs for data presented herein are as follows:
Bioconductor: Open Source Software for Bioinformatics, http://
www.bioconductor.org/
dbGAP. http://www.ncbi.nlm.nih.gov/gap
FPCA for Association Studies, https://sph.uth.tmc.edu/hgc/
faculty/xiong/software-A.html
NCBI Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/
geo/References
1. Rakyan, V.K., Down, T.A., Balding, D.J., and Beck, S. (2011).
Epigenome-wide association studies for common human
diseases. Nat. Rev. Genet. 12, 529–541.1044 The American Journal of Human Genetics 90, 1028–1045, June2. Neale, B.M., Rivas, M.A., Voight, B.F., Altshuler, D., Devlin, B.,
Orho-Melander, M., Kathiresan, S., Purcell, S.M., Roeder, K.,
and Daly, M.J. (2011). Testing for an unusual distribution of
rare variants. PLoS Genet. 7, e1001322.
3. Bansal, V., Libiger, O., Torkamani, A., and Schork, N.J. (2010).
Statistical analysis strategies for association studies involving
rare variants. Nat. Rev. Genet. 11, 773–785.
4. Chaisson, M.J., Brinza, D., and Pevzner, P.A. (2009). De novo
fragment assembly with short mate-paired reads: Does the
read length matter? Genome Res. 19, 336–346.
5. Johnson, P.L., and Slatkin,M. (2008). Accounting for bias from
sequencing error in population genetic estimates. Mol. Biol.
Evol. 25, 199–206.
6. Lynch, M. (2009). Estimation of allele frequencies from high-
coverage genome-sequencing projects. Genetics 182, 295–301.
7. Pool, J.E., Hellmann, I., Jensen, J.D., and Nielsen, R. (2010).
Population genetic inference from genomic sequence varia-
tion. Genome Res. 20, 291–300.
8. Lupski, J.R., Belmont, J.W., Boerwinkle, E., and Gibbs, R.A.
(2011). Clan genomics and the complex architecture of
human disease. Cell 147, 32–43.
9. Li, B., and Leal, S.M. (2008). Methods for detecting associa-
tions with rare variants for common diseases: application to
analysis of sequence data. Am. J. Hum. Genet. 83, 311–321.
10. Najmabadi, H., Hu, H., Garshasbi, M., Zemojtel, T., Abedini,
S.S., Chen, W., Hosseini, M., Behjati, F., Haas, S., Jamali, P.,
et al. (2011). Deep sequencing reveals 50 novel genes for reces-
sive cognitive disorders. Nature 478, 57–63.
11. Chakravarti, A. (2011). Genomics is not enough. Science
334, 15.
12. Ott, J., Kamatani, Y., and Lathrop, M. (2011). Family-based
designs for genome-wide association studies. Nat. Rev. Genet.
12, 465–474.
13. Choi, Y., Wijsman, E.M., and Weir, B.S. (2009). Case-control
association testing in the presence of unknown relationships.
Genet. Epidemiol. 33, 668–678.
14. Bourgain, C., Hoffjan, S., Nicolae, R., Newman, D., Steiner, L.,
Walker, K., Reynolds, R., Ober, C., and McPeek, M.S. (2003).
Novel case-control test in a founder population identifies
P-selectin as an atopy-susceptibility locus. Am. J. Hum. Genet.
73, 612–626.
15. Thornton, T., and McPeek, M.S. (2007). Case-control associa-
tion testing with related individuals: a more powerful quasi-
likelihood score test. Am. J. Hum. Genet. 81, 321–337.
16. Thornton, T., and McPeek, M.S. (2010). ROADTRIPS: case-
control association testing with partially or completely
unknown population and pedigree structure. Am. J. Hum.
Genet. 86, 172–184.
17. Xiong, M., Zhao, J., and Boerwinkle, E. (2002). Generalized T2
test for genome association studies. Am. J. Hum. Genet. 70,
1257–1268.
18. Luo, L., Boerwinkle, E., and Xiong, M. (2011). Association
studies for next-generation sequencing. Genome Res. 21,
1099–1108.
19. Yang, J., Benyamin, B., McEvoy, B.P., Gordon, S., Henders,
A.K., Nyholt, D.R., Madden, P.A., Heath, A.C., Martin, N.G.,
Montgomery, G.W., et al. (2010). Common SNPs explain
a large proportion of the heritability for human height. Nat.
Genet. 42, 565–569.
20. Lambert, B.W., Terwilliger, J.D., andWeiss, K.M. (2008). ForSim:
a tool for exploring the genetic architecture of complex traits
with controlled truth. Bioinformatics 24, 1821–1822.8, 2012
21. Li, Y., Byrnes, A.E., and Li, M. (2010). To identify associations
with rare variants, just WHaIT: Weighted haplotype and
imputation-based tests. Am. J. Hum. Genet. 87, 728–735.
22. Larson, M.G., Atwood, L.D., Benjamin, E.J., Cupples, L.A.,
D’Agostino, R.B., Sr., Fox, C.S., Govindaraju, D.R., Guo, C.Y.,
Heard-Costa,N.L.,Hwang, S.J., et al. (2007). FraminghamHeart
Study 100K project: genome-wide associations for cardiovas-
cular disease outcomes. BMCMed. Genet. 8 (Suppl 1 ), S5.
23. Dai, H., Zhang, L., Cao, M., Song, F., Zheng, H., Zhu, X., Wei,
Q., Zhang, W., and Chen, K. (2011). The role of polymor-
phisms in circadian pathway genes in breast tumorigenesis.
Breast Cancer Res. Treat. 127, 531–540.
24. Eisele, L., Prinz, R., Klein-Hitpass, L., Nu¨ckel, H., Lowinski, K.,
Thomale, J., Moeller, L.C., Du¨hrsen, U., and Du¨rig, J. (2009).
Combined PER2 and CRY1 expression predicts outcome in
chronic lymphocytic leukemia. Eur. J. Haematol. 83, 320–327.
25. Zhang, P., Hou, M., Li, Y., Xu, X., Barsoum, M., Chen, Y.J., and
Bache, R.J. (2009). NADPH oxidase contributes to coronary
endothelial dysfunction in the failing heart. Am. J. Physiol.
Heart Circ. Physiol. 296, H840–H846.
26. Kaur, T., Mukherjea, D., Sheehan, K., Jajoo, S., Rybak, L.P., and
Ramkumar, V. (2011). Short interfering RNA against STAT1
attenuates cisplatin-induced ototoxicity in the rat by sup-
pressing inflammation. Cell Death Dis. 2, e180.
27. Talmud, P.J., Drenos, F., Shah, S., Shah, T., Palmen, J., Verzilli,
C., Gaunt, T.R., Pallas, J., Lovering, R., Li, K., et al; ASCOT
investigators; NORDIL investigators; BRIGHT Consortium.
(2009). Gene-centric association signals for lipids and apolipo-The Americproteins identified via the HumanCVD BeadChip. Am. J.
Hum. Genet. 85, 628–642.
28. Hendrickson, S.L., Lautenberger, J.A., Chinn, L.W., Malasky,
M., Sezgin, E., Kingsley, L.A., Goedert, J.J., Kirk, G.D.,
Gomperts, E.D., Buchbinder, S.P., et al. (2010). Genetic vari-
ants in nuclear-encoded mitochondrial genes influence AIDS
progression. PLoS ONE 5, e12862.
29. Yan, J., and Jetten, A.M. (2008). RAP80 and RNF8, key players
in the recruitment of repair proteins to DNA damage sites.
Cancer Lett. 271, 179–190.
30. Osorio, A., Barroso, A., Garcı´a, M.J., Martı´nez-Delgado, B.,
Urioste, M., and Benı´tez, J. (2009). Evaluation of the BRCA1
interacting genes RAP80 and CCDC98 in familial breast
cancer susceptibility. Breast Cancer Res. Treat. 113, 371–376.
31. Moffatt, M.F., Kabesch, M., Liang, L., Dixon, A.L., Strachan,
D., Heath, S., Depner, M., von Berg, A., Bufe, A., Rietschel,
E., et al. (2007). Genetic variants regulating ORMDL3 expres-
sion contribute to the risk of childhood asthma. Nature 448,
470–473.
32. Risch, N., and Merikangas, K. (1996). The future of genetic
studies of complex human diseases. Science 273, 1516–1517.
33. Clerget-Darpoux, F., and Elston, R.C. (2007). Are linkage anal-
ysis and the collection of family data dead? Prospects for
family studies in the age of genome-wide association. Hum.
Hered. 64, 91–96.
34. Henderson, D., and Plaschko, P. (2006). Stochastic differential
equations in science and engineering (New Jersey: World
Scientific).an Journal of Human Genetics 90, 1028–1045, June 8, 2012 1045
